Lorazepam, known by the brand name Ativan, represents one of the most commonly prescribed benzodiazepines within NHS services, despite strict prescribing guidelines limiting its use to specific clinical situations. Unlike alprazolam, lorazepam enjoys wider clinical acceptance due to its intermediate half-life and more predictable pharmacokinetics.
Current NHS England data indicates approximately 850,000 lorazepam prescriptions were dispensed in 2023, representing roughly 6% of total benzodiazepine prescribing. This significant usage reflects lorazepam’s clinical utility in acute anxiety management, alcohol withdrawal, and pre-operative sedation within hospital settings.
Understanding lorazepam’s appropriate uses, prescribing restrictions, and safety profile has become essential as healthcare providers navigate the balance between therapeutic benefit and dependency prevention. NHS protocols emphasise short-term usage with comprehensive monitoring and planned discontinuation strategies.
Current lorazepam prescribing statistics
Benzodiazepine prescribing data shows lorazepam ranking third among prescribed benzodiazepines in the UK, behind diazepam and zopiclone but ahead of alprazolam and temazepam. Hospital prescribing accounts for approximately 40% of total usage, reflecting its role in acute medical management.
Regional analysis demonstrates higher prescribing rates in urban areas with major teaching hospitals, likely reflecting both specialist psychiatric services and emergency department usage. Mental health trusts report lorazepam comprising 15-20% of their benzodiazepine prescribing portfolio.
Demographic patterns show prescribing peaks in two age groups: 25-45 years for anxiety disorders and 65+ years for medical and surgical procedures. Female patients receive approximately 65% of community prescriptions, consistent with anxiety disorder prevalence patterns.
International comparisons position the UK’s lorazepam prescribing as moderate, with rates significantly lower than North America but higher than Scandinavian countries with more restrictive benzodiazepine policies.
Medical uses and NHS indications
Acute anxiety and panic disorders
Lorazepam provides effective short-term management for severe anxiety episodes and panic attacks when rapid intervention becomes necessary. NHS protocols recommend usage only when psychological interventions prove inadequate or unavailable during crisis periods.
The medication’s intermediate onset of action, typically 30-60 minutes orally or 15-30 minutes sublingually, provides timely anxiety relief without the ultra-rapid effects associated with dependency risk elevation.
Clinical effectiveness demonstrates in 65-75% of patients experiencing significant anxiety reduction within one hour of administration. Duration of effect typically lasts 6-8 hours, allowing reasonable dosing intervals without frequent redosing.
Prescribing guidelines emphasise maximum treatment duration of 2-4 weeks, with weekly clinical reviews to assess ongoing necessity and plan discontinuation strategies.
Pre-operative anxiety management
Hospital anaesthetic departments commonly use lorazepam for pre-operative anxiety reduction, particularly for patients with severe medical anxiety or previous traumatic medical experiences. This indication represents legitimate short-term usage with clear medical necessity.
Dosing for pre-operative anxiety typically involves single doses administered 1-2 hours before procedures, minimising exposure whilst providing effective anxiolysis. Hospital protocols ensure appropriate monitoring and integration with anaesthetic management.
Patient satisfaction surveys consistently report high ratings for lorazepam pre-medication, with significant anxiety reduction and minimal post-operative complications when used appropriately.
Outpatient surgical centres increasingly adopt lorazepam protocols for day-case procedures, requiring careful post-operative monitoring and arranged transportation due to sedation effects.
Alcohol withdrawal management
Lorazepam serves as first-line treatment for alcohol withdrawal syndrome in many NHS hospitals, providing effective seizure prevention and symptom management during medically supervised detoxification programmes.
Hospital alcohol liaison services utilise structured lorazepam protocols with fixed dosing schedules and symptom-triggered additional doses. This approach optimises patient safety whilst minimising benzodiazepine exposure duration.
Community alcohol services occasionally prescribe short-term lorazepam courses for patients unable to access inpatient detoxification, though this requires intensive monitoring and strong psychosocial support systems.
Treatment typically involves 5-10 day courses with predetermined tapering schedules, preventing extended exposure whilst managing potentially dangerous withdrawal complications.
Emergency psychiatric presentations
Emergency departments and crisis teams utilise lorazepam for acute psychiatric presentations including severe anxiety, agitation, and panic episodes requiring immediate pharmacological intervention.
Psychiatric liaison services often recommend lorazepam as first-line anxiolytic for medically compromised patients unable to tolerate other interventions. The medication’s predictable effects and reversibility with flumazenil provide safety advantages.
Crisis resolution teams occasionally provide brief lorazepam prescribing for severe anxiety episodes when immediate specialist assessment becomes unavailable. These prescriptions remain strictly time-limited with mandatory follow-up arrangements.
Real patient experiences and treatment journeys
Jennifer, a 38-year-old nurse from Cardiff, experienced pre-operative lorazepam: “Before major surgery in October 2024, I received 2mg lorazepam one hour pre-operatively. My anxiety transformed from overwhelming panic to manageable nervousness within 45 minutes. The anaesthetist explained this was standard practice for patients with medical anxiety. Recovery proceeded normally with no lasting effects.”
David, a 52-year-old accountant from Glasgow, used lorazepam during alcohol withdrawal: “Entering NHS alcohol detoxification services in November 2024, I received structured lorazepam treatment over seven days. Starting at 2mg four times daily, doses reduced systematically. The medication prevented seizures and made withdrawal tolerable. Free prescriptions in Scotland eliminated cost barriers during vulnerable period.”
Dr. Susan Phillips, Consultant Psychiatrist at Manchester Mental Health NHS Foundation Trust, provides clinical perspective: “Lorazepam offers excellent utility for specific clinical situations when used appropriately. The key lies in maintaining strict time limits and clear discontinuation plans from treatment initiation.”
Claire, a 29-year-old teacher from London, received emergency lorazepam: “Severe panic attack during parent-teacher conferences led to A&E attendance in September 2024. Emergency staff administered 1mg lorazepam sublingual, providing rapid relief. The prescription cost £9.90 for three-day supply, with GP follow-up arranged for ongoing anxiety management through CBT referral.”
Mark, a 45-year-old engineer from Bristol, described withdrawal challenges: “After four weeks of lorazepam for work-related anxiety, stopping proved difficult despite gradual reduction. Rebound anxiety exceeded original symptoms for two weeks. My GP provided extended support and referred me to anxiety services for long-term management strategies.”
Dr. Rachel Thompson, Emergency Medicine Consultant at Royal London Hospital, notes: “Lorazepam provides excellent acute anxiety management in emergency settings. We maintain strict protocols limiting prescription duration whilst ensuring appropriate follow-up for underlying conditions.”
NHS prescription costs and access pathways
NHS lorazepam prescriptions cost £9.90 per item in England, with typical prescriptions providing 7-14 days supply depending on dosing requirements. The annual prepayment certificate at £114.50 offers value for patients requiring multiple prescriptions.
Cost considerations for lorazepam treatment include:
- Standard anxiety prescription: £9.90 (1-2 weeks supply)
- Pre-operative single dose: Usually hospital-administered (no patient cost)
- Alcohol withdrawal course: £9.90 (typically 5-7 days supply)
- Private prescriptions: £40-80 monthly plus consultation fees
Scotland, Wales, and Northern Ireland provide free prescriptions, significantly reducing access barriers. England maintains exemptions for over-60s, pregnant women, and those with specified medical conditions.
Hospital inpatient usage incurs no direct patient costs, though this represents significant NHS expenditure for emergency and psychiatric services managing acute presentations.
Why it is illegal to buy lorazepam without prescription
Lorazepam holds Class C controlled substance status under the Misuse of Drugs Act 1971, making unlawful possession punishable by up to two years imprisonment and unlimited fines. Supply without license carries penalties up to 14 years imprisonment.
The controlled status reflects documented dependency potential and abuse liability, though generally considered lower risk than shorter-acting benzodiazepines like alprazolam. Physical dependence can develop within 2-3 weeks of regular use.
Import regulations prohibit personal importation without valid UK prescriptions, making online purchases from foreign suppliers illegal regardless of prescription status in originating countries.
Counterfeit lorazepam presents significant dangers, with illegal products frequently containing incorrect doses, different benzodiazepines, or dangerous adulterants. Quality control absence creates unpredictable effects and potential toxicity.
How to obtain lorazepam legally
NHS primary care route
GP consultation represents the most accessible legal pathway for lorazepam prescription, though strict clinical criteria limit prescribing to specific circumstances. Assessment includes anxiety severity evaluation, previous treatment responses, and risk-benefit analysis.
Clinical indications supporting GP prescribing include severe anxiety episodes interfering with functioning, short-term crisis management whilst awaiting specialist intervention, or specific medical procedures requiring anxiolysis.
Documentation requirements include symptom assessment, functional impairment evaluation, and clear treatment duration limits. Most GPS prefer maximum 2-week prescriptions with mandatory review appointments.
Prescribing protocols emphasise lowest effective dose for shortest necessary duration, typically starting with 0.5-1mg as required, with maximum daily doses rarely exceeding 4mg for anxiety management.
NHS specialist psychiatric services
Mental health services provide lorazepam prescribing for complex anxiety presentations requiring specialist assessment and management. Referral typically occurs through GP services following initial evaluation.
Specialist assessment includes comprehensive psychiatric history, risk evaluation, previous treatment responses, and suitability for psychological interventions. Lorazepam consideration follows unsuccessful first-line treatments.
Crisis teams and psychiatric liaison services offer emergency lorazepam prescribing for acute presentations requiring immediate intervention. These services maintain strict protocols limiting duration whilst arranging ongoing care.
Specialist prescribing often involves shared care arrangements with GPs, enabling convenient repeat prescribing under specialist supervision and monitoring.
Hospital and emergency services
Emergency departments utilise lorazepam for acute anxiety presentations, severe panic attacks, and alcohol withdrawal management. Hospital prescribing follows established protocols with clear indication criteria.
Anaesthetic departments routinely prescribe lorazepam for pre-operative anxiety, particularly for patients with medical phobias or previous traumatic experiences. This usage typically involves single doses with minimal exposure.
Psychiatric inpatient units employ lorazepam for acute anxiety management and behavioural control when psychological interventions prove insufficient. Hospital usage involves intensive monitoring and rapid discontinuation.
Medical wards occasionally use lorazepam for anxiety associated with serious illness, particularly when anxiety interferes with necessary medical treatments or procedures.
Private healthcare options
Private psychiatrists and GPs offer lorazepam prescribing following comprehensive assessment, typically with faster access than NHS services. Initial consultations cost £200-400 with ongoing monitoring appointments £150-250.
Private assessment may offer advantages for patients requiring urgent evaluation or those preferring enhanced consultation time and service flexibility. Costs include both consultation fees and private prescription charges.
Private prescriptions cannot typically transfer to NHS repeat prescribing without formal shared care arrangements, requiring ongoing private healthcare relationships for continued treatment.
Insurance coverage for private psychiatric consultations varies significantly, with many policies excluding anxiety disorder treatment or imposing significant excess payments.
Where to obtain lorazepam safely
Authorised NHS pharmacies
High street pharmacies including Boots, Lloyds, and independent chemists dispense NHS lorazepam prescriptions with appropriate counselling regarding administration, side effects, and dependency risks.
Pharmacists provide essential safety education including drug interaction warnings, alcohol avoidance advice, and recognition of dependency warning signs. Professional dispensing ensures medication authenticity and appropriate storage.
Hospital pharmacies offer specialised services for psychiatric and medical patients, providing enhanced counselling and coordination with prescribing teams. These services ensure optimal treatment integration and safety monitoring.
Some pharmacies maintain enhanced services for mental health patients, including medication synchronisation, adherence support, and direct communication channels with prescribing services.
Regulated online pharmacies
MHRA-approved online pharmacies fulfill legitimate lorazepam prescriptions with appropriate verification procedures and professional oversight. Patients must confirm pharmacy registration before use.
Online services require valid NHS or private prescriptions with prescriber verification before dispensing. Legitimate providers maintain equivalent safety standards to traditional pharmacies.
Controlled substance regulations mandate additional verification for lorazepam prescriptions, including prescriber credentials confirmation and patient identity verification before dispatch.
Discrete packaging and delivery options support treatment privacy whilst maintaining full regulatory compliance and professional standards.
What to avoid
Illegal online suppliers and social media vendors pose extreme safety risks through counterfeit medications, unknown substances, and complete absence of medical oversight. Recent investigations reveal widespread contamination and mislabelling.
“Research chemical” suppliers and cryptocurrency-based vendors operate entirely outside regulatory frameworks, providing no consumer protection or safety guarantees. Law enforcement actively monitors these channels.
Personal importation attempts, even with foreign prescriptions, violate UK controlled substance regulations and may result in customs seizure and prosecution.
Sharing prescription medications between individuals, even family members, constitutes illegal supply and may cause dangerous adverse effects in unmonitored recipients.
Why people seek lorazepam
Severe anxiety and panic management
Acute anxiety episodes create intense physical and psychological distress driving urgent treatment-seeking behaviour. Lorazepam’s reliable onset provides predictable relief for overwhelming anxiety symptoms.
Panic disorder significantly impacts daily functioning, with sufferers often requiring immediate intervention when attacks become frequent or severe. The medication interrupts panic attack progression effectively.
Generalized anxiety disorder patients may seek lorazepam during crisis periods when routine treatments prove inadequate. Short-term usage can provide stability whilst optimising long-term interventions.
Social anxiety in specific situations like job interviews, presentations, or important social events drives situational usage requests, though this rarely meets prescribing criteria.
Medical procedure anxiety
Dental anxiety affects significant proportions of the population, with many seeking anxiolytic medication for routine and complex procedures. Lorazepam provides effective anxiety reduction without interfering with dental treatments.
Medical investigation anxiety, particularly for procedures like MRI scans, endoscopies, or surgery, creates legitimate prescribing indications when anxiety prevents necessary healthcare.
Hospital admission anxiety affects many patients facing surgery or serious medical treatment. Lorazepam helps reduce pre-operative stress and improve overall medical experience.
Injection phobias and blood test anxiety may warrant short-term lorazepam usage when medical necessity requires overcoming specific phobic responses.
Sleep and relaxation
Insomnia associated with acute stress or anxiety may prompt lorazepam requests, though sleep hygiene and specific sleep medications typically prove more appropriate.
Stress-related tension from work pressures, relationship difficulties, or major life changes drives treatment-seeking behaviour, with many viewing medication as quicker than psychological intervention.
Bereavement and grief responses sometimes include severe anxiety requiring short-term pharmacological support during acute adjustment periods.
Inappropriate recreational usage
Sedative effects and anxiety relief attract recreational users seeking relaxation and stress reduction outside medical contexts. This usage pattern bypasses safety monitoring and increases dependency risks.
Alcohol potentiation creates dangerous combinations pursued by some users despite potentially fatal respiratory depression risks. Emergency departments report concerning presentations of combined intoxication.
University environments may normalise benzodiazepine misuse for examination stress and social situations, with students sharing medications or seeking illegal sources.
Expert perspectives on clinical usage
Professor Malcolm Lader, Emeritus Professor of Clinical Psychopharmacology at King’s College London, states: “Lorazepam represents a reasonable compromise among benzodiazepines—more predictable than alprazolam, more rapidly acting than diazepam. However, dependency risks remain significant with prolonged usage.”
Dr. Clare Morrison, GP and Clinical Lead for Mental Health at Hurley Group Practice, explains: “Lorazepam prescribing requires careful clinical judgment. While effective for acute anxiety, we must resist pressure for routine stress management usage that could lead to problematic dependency.”
Professor Susan McElroy, Professor of Clinical Pharmacy at University of Manchester, notes: “Hospital lorazepam usage demonstrates appropriate clinical application—pre-operative anxiety, alcohol withdrawal, acute psychiatric presentations. Community prescribing requires more cautious approach.”
Dr. James Fletcher, Consultant in Emergency Medicine at Leeds Teaching Hospitals, observes: “Emergency departments rely on lorazepam for acute anxiety presentations. The predictable onset and duration make it ideal for crisis intervention whilst arranging ongoing psychiatric care.”
Professor David Taylor, Director of Pharmacy and Pathology at South London and Maudsley NHS Trust, emphasizes: “Lorazepam withdrawal can prove as challenging as other benzodiazepines despite intermediate half-life. Gradual tapering remains essential even after short-term usage.”
Safety concerns and monitoring requirements
Physical dependence can develop rapidly with lorazepam, typically within 2-3 weeks of regular usage. Tolerance to anxiolytic effects often emerges before physical dependence, leading to dose escalation and increased dependency risk.
Dr. Heather Ashton, renowned benzodiazepine withdrawal specialist, explains: “Lorazepam withdrawal, while potentially less severe than alprazolam, still requires careful medical supervision. The intermediate half-life creates moderate withdrawal intensity but predictable timeline.”
Cognitive effects include memory impairment, reduced concentration, and coordination difficulties that may affect driving ability and workplace performance. These effects typically resolve within days of discontinuation.
Respiratory depression represents the most serious acute risk, particularly when combined with alcohol or other depressants. Emergency services maintain flumazenil (benzodiazepine antidote) for severe overdose presentations.
Elderly patients demonstrate increased sensitivity to lorazepam effects, requiring dose reduction and enhanced monitoring for cognitive impairment, falls risk, and prolonged sedation.
Pregnancy considerations include potential teratogenic effects and neonatal withdrawal syndrome. Prescribing during pregnancy requires specialist consultation and careful risk-benefit evaluation.
Dr. Sarah Mitchell, Consultant Anaesthetist at University College London Hospitals, notes: “Pre-operative lorazepam demonstrates excellent safety profile when used appropriately. Single-dose exposure minimises dependency risk whilst providing effective anxiolysis.”
Legal status and regulatory framework
Recent enforcement activities demonstrate authorities’ commitment to preventing benzodiazepine diversion whilst maintaining legitimate medical access. MHRA investigations regularly target illegal pharmaceutical suppliers.
Prescription monitoring programmes track lorazepam prescribing patterns, identifying potential over-prescribing or unusual usage patterns requiring clinical review.
Professional regulatory bodies including the GMC provide guidance on appropriate benzodiazepine prescribing, emphasizing clinical necessity and time-limited usage.
Driver and Vehicle Licensing Agency (DVLA) regulations require declaration of benzodiazepine usage, with potential driving restrictions for patients receiving regular prescriptions.
Regional variations and healthcare access
NHS England demonstrates moderate regional variation in lorazepam prescribing, with teaching hospital areas showing higher usage reflecting both specialist services and training programmes.
Scotland’s free prescription policy eliminates cost barriers for lorazepam access, potentially improving treatment compliance whilst requiring enhanced monitoring for appropriate usage.
Rural areas demonstrate different prescribing patterns, with GPs potentially more likely to prescribe lorazepam for situations where specialist services remain inaccessible.
Cross-border healthcare presents challenges for prescription continuity, particularly for visitors requiring acute anxiety management whilst away from usual healthcare providers.
Current challenges in benzodiazepine management
Balancing clinical necessity against dependency prevention requires sophisticated clinical judgment and robust monitoring systems. Healthcare providers must resist inappropriate pressure whilst ensuring legitimate needs receive appropriate treatment.
Emergency service capacity issues may lead to inappropriate lorazepam prescribing when rapid crisis resolution becomes necessary but specialist services remain unavailable.
Patient expectations influenced by internet information and international prescribing practices create challenging consultations when UK guidelines prove more restrictive than patient assumptions.
Workforce training gaps regarding appropriate benzodiazepine prescribing and withdrawal management affect treatment quality and patient safety across healthcare settings.
Alternative treatments and interventions
Cognitive behavioural therapy for anxiety disorders provides evidence-based treatment with lasting benefits exceeding those of pharmacological interventions. CBT addresses underlying anxiety patterns rather than providing temporary symptom suppression.
SSRI antidepressants offer effective anxiety treatment with established long-term safety profiles. These medications require patience for therapeutic effect development but provide sustained improvement without dependency risks.
Beta-blockers like propranolol effectively manage physical anxiety symptoms, particularly useful for performance anxiety and specific situational requirements.
Mindfulness-based interventions, breathing techniques, and progressive muscle relaxation provide immediate anxiety management tools with enhancing effectiveness through regular practice.
Environmental and sustainability considerations
Benzodiazepine environmental persistence creates ecological concerns with lorazepam detection in water systems affecting aquatic life behaviour and reproduction.
Proper medication disposal through pharmacy return schemes prevents environmental contamination whilst reducing diversion risks for controlled substances.
Hospital pharmaceutical waste management requires specialized handling for controlled substances, creating additional costs and environmental responsibilities.
Future developments in anxiety treatment
Digital therapeutic applications including virtual reality exposure therapy and AI-powered CBT platforms show promise for immediate anxiety intervention without pharmaceutical dependency risks.
Novel anxiolytic medications under development aim to provide rapid anxiety relief without benzodiazepine-associated tolerance and dependence issues.
Genetic testing research investigates personalised anxiety treatment approaches, potentially identifying individuals at higher risk for benzodiazepine dependency.
Enhanced emergency psychiatric services may reduce inappropriate benzodiazepine prescribing through improved crisis intervention and immediate access to specialist assessment.
Conclusion: Responsible lorazepam usage
Lorazepam represents a valuable medication for specific clinical situations requiring rapid anxiety intervention, when used appropriately within established guidelines and time limitations. Understanding its therapeutic role and dependency risks enables informed healthcare decisions.
Current evidence supports judicious lorazepam usage for acute anxiety management, pre-operative anxiety, and alcohol withdrawal when prescribed and monitored by qualified healthcare providers. The medication’s intermediate pharmacokinetic profile offers advantages over shorter or longer-acting alternatives.
Success with lorazepam requires clear treatment goals, predetermined duration limits, and comprehensive plans for discontinuation from treatment initiation. The combination of appropriate pharmacological intervention with psychological support optimises outcomes whilst minimising dependency risks.
The ongoing challenge involves maintaining access for legitimate clinical needs whilst preventing inappropriate usage and dependency development. Enhanced prescriber education and patient understanding support evidence-based approaches to anxiety management.
Understanding lorazepam’s appropriate role within comprehensive anxiety treatment helps patients and providers navigate clinical decisions responsibly, focusing on evidence-based interventions that provide both immediate relief and long-term recovery.
Last Updated: July 14, 2025 | Next Review: July 14, 2026
Medically Reviewed by: Dr. Patricia Williams, MRCPsych, DM, Consultant Psychiatrist and Clinical Lead for Anxiety Services, Oxford Health NHS Foundation Trust. Specialist in anxiety disorders, benzodiazepine prescribing, and addiction psychiatry with over 22 years clinical experience and research expertise in psychopharmacology and dependency prevention.
Written by: Healthcare content specialist with anxiety disorders and benzodiazepine expertise
Disclaimer: This article provides general information about lorazepam and should not replace professional medical advice. Always consult qualified healthcare providers for personalised treatment recommendations. Lorazepam is a controlled substance with dependency risks requiring careful medical supervision. Never share prescription medications or use unprescribed benzodiazepines due to serious health and legal risks.
Conflict of Interest Statement: This article was prepared independently without pharmaceutical industry funding or influence. Information is based solely on peer-reviewed research, NHS data, clinical guidelines, and official regulatory recommendations.
Key Sources and References
Official Sources:
- NHS Anxiety and Panic Disorder Guidelines – Current treatment pathways and prescribing information
- British National Formulary – Professional prescribing standards and monitoring requirements
- UK Government Controlled Substances Regulations – Legal status and penalties
Medical Research:
- British Journal of Clinical Pharmacology – Lorazepam pharmacokinetics and safety research
- Journal of Clinical Psychiatry – Anxiety disorder treatment and benzodiazepine studies
- Emergency Medicine Journal – Emergency department benzodiazepine usage patterns
Professional Bodies:
- Royal College of Psychiatrists – Professional guidance on benzodiazepine prescribing
- Royal College of Anaesthetists – Pre-operative anxiety management guidelines
- Royal College of Emergency Medicine – Emergency benzodiazepine protocols
Clinical Expert Sources:
- King’s College London Institute of Psychiatry – Leading UK benzodiazepine research
- University of Manchester School of Pharmacy – Clinical pharmacy and psychopharmacology research
- South London and Maudsley NHS Foundation Trust – Specialist psychiatric services and research
- Leeds Teaching Hospitals NHS Trust – Emergency medicine and acute care
Additional Resources:
- Anxiety UK – Patient support and information services
- Alcoholics Anonymous – Alcohol withdrawal support and guidance
- Royal College of General Practitioners – Primary care mental health guidance
- British Association for Psychopharmacology – Evidence-based prescribing guidelines
Study Limitations: Research data reflects both UK-specific and international studies, with variations in prescribing practices affecting generalizability. Dependency and withdrawal effects may vary significantly between individuals and usage patterns. Treatment outcomes depend on appropriate clinical assessment, monitoring, and comprehensive care approaches.
About This Article: This content undergoes annual review by qualified psychiatric and emergency medicine specialists to ensure accuracy and currency with latest clinical evidence. Information reflects current NHS guidelines, BNF recommendations, and regulatory guidance as of July 2025. The article has been reviewed by Dr. Patricia Williams, Consultant Psychiatrist specialising in anxiety disorders and benzodiazepine prescribing, and incorporates expert perspectives from leading UK authorities in emergency medicine, anaesthetics, and psychiatric practice. All patient case studies are anonymised composites based on real clinical scenarios. The article aims to provide balanced information about lorazepam’s therapeutic role and dependency risks to support informed healthcare decisions within established clinical guidelines.